PURPOSE: Uncertainty remains about the impact of bilateral breast cancer. Characteristics and outcomes of unilateral and bilateral breast cancer were compared within an Australian multi-institutional cohort. METHODS: Demographic, tumour and treatment characteristics were compared among unilateral (n = 2336) and bilateral cases (52 synchronous, 35 metachronous) using descriptive analyses. Disease-specific outcomes were investigated using Cox regression modelling to adjust for prognostic and treatment factors. RESULTS: Factors associated with increased risk of bilateral breast cancer included lobular histology (p = 0.046), family history (p = 0.025) and metropolitan residence (p = 0.006). Mastectomy was more common for bilateral cases (p = 0.001) while radiotherapy was less common (p = 0.015). Index metachronous cases were less likely to receive hormonal therapy (p = 0.001). Five-year survivals for metachronous, synchronous and unilateral cases were 79%, 88% and 94%, respectively. Poorer outcomes remained after adjusting for prognostic factors [HR = 2.26, 1.21-4.21]. CONCLUSION: Our results confirm international findings indicating worse outcomes from bilateral compared with unilateral breast cancer.
PURPOSE: Uncertainty remains about the impact of bilateral breast cancer. Characteristics and outcomes of unilateral and bilateral breast cancer were compared within an Australian multi-institutional cohort. METHODS: Demographic, tumour and treatment characteristics were compared among unilateral (n = 2336) and bilateral cases (52 synchronous, 35 metachronous) using descriptive analyses. Disease-specific outcomes were investigated using Cox regression modelling to adjust for prognostic and treatment factors. RESULTS: Factors associated with increased risk of bilateral breast cancer included lobular histology (p = 0.046), family history (p = 0.025) and metropolitan residence (p = 0.006). Mastectomy was more common for bilateral cases (p = 0.001) while radiotherapy was less common (p = 0.015). Index metachronous cases were less likely to receive hormonal therapy (p = 0.001). Five-year survivals for metachronous, synchronous and unilateral cases were 79%, 88% and 94%, respectively. Poorer outcomes remained after adjusting for prognostic factors [HR = 2.26, 1.21-4.21]. CONCLUSION: Our results confirm international findings indicating worse outcomes from bilateral compared with unilateral breast cancer.
Authors: Colin B Begg; Irina Ostrovnaya; Felipe C Geyer; Anastasios D Papanastasiou; Charlotte K Y Ng; Rita A Sakr; Jonine L Bernstein; Kathleen A Burke; Tari A King; Salvatore Piscuoglio; Audrey Mauguen; Irene Orlow; Britta Weigelt; Venkatraman E Seshan; Monica Morrow; Jorge S Reis-Filho Journal: Int J Cancer Date: 2017-09-28 Impact factor: 7.396
Authors: Elżbieta Senkus; Jolanta Szade; Beata Pieczyńska; Anna Zaczek; Joanna Pikiel; Katarzyna Sosińska-Mielcarek; Agnieszka Karpińska; Jacek Jassem Journal: Int J Clin Exp Pathol Date: 2013-12-15
Authors: Anne S Reiner; Esther M John; Jennifer D Brooks; Charles F Lynch; Leslie Bernstein; Lene Mellemkjær; Kathleen E Malone; Julia A Knight; Marinela Capanu; Sharon N Teraoka; Patrick Concannon; Xiaolin Liang; Jane C Figueiredo; Susan A Smith; Marilyn Stovall; Malcolm C Pike; Robert W Haile; Duncan C Thomas; Colin B Begg; Jonine L Bernstein Journal: J Clin Oncol Date: 2012-12-26 Impact factor: 44.544